JPWO2019165140A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019165140A5 JPWO2019165140A5 JP2020543145A JP2020543145A JPWO2019165140A5 JP WO2019165140 A5 JPWO2019165140 A5 JP WO2019165140A5 JP 2020543145 A JP2020543145 A JP 2020543145A JP 2020543145 A JP2020543145 A JP 2020543145A JP WO2019165140 A5 JPWO2019165140 A5 JP WO2019165140A5
- Authority
- JP
- Japan
- Prior art keywords
- subject
- fusion protein
- administered
- weeks
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108020001507 fusion proteins Proteins 0.000 claims 44
- 102000037240 fusion proteins Human genes 0.000 claims 44
- 239000003814 drug Substances 0.000 claims 39
- 206010018651 Graft versus host disease Diseases 0.000 claims 30
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 30
- 229940079593 drugs Drugs 0.000 claims 16
- 206010021972 Inflammatory bowel disease Diseases 0.000 claims 12
- 230000001154 acute Effects 0.000 claims 12
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 241000349774 Bikinia letestui Species 0.000 claims 6
- 206010009900 Colitis ulcerative Diseases 0.000 claims 6
- 230000003042 antagnostic Effects 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 230000004044 response Effects 0.000 claims 6
- 201000006704 ulcerative colitis Diseases 0.000 claims 6
- 206010038063 Rectal haemorrhage Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 229920001184 polypeptide Polymers 0.000 claims 5
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims 4
- 238000002560 therapeutic procedure Methods 0.000 claims 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 3
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 claims 3
- 239000003018 immunosuppressive agent Substances 0.000 claims 3
- 108010027445 interleukin-22 receptor Proteins 0.000 claims 3
- 210000000056 organs Anatomy 0.000 claims 3
- 239000008177 pharmaceutical agent Substances 0.000 claims 3
- 230000004083 survival Effects 0.000 claims 3
- 206010011401 Crohn's disease Diseases 0.000 claims 2
- 210000000936 Intestines Anatomy 0.000 claims 2
- 210000004185 Liver Anatomy 0.000 claims 2
- 210000003491 Skin Anatomy 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001684 chronic Effects 0.000 claims 2
- 230000002496 gastric Effects 0.000 claims 2
- 125000000267 glycino group Chemical group [H]N([*])C([H])([H])C(=O)O[H] 0.000 claims 2
- 230000035876 healing Effects 0.000 claims 2
- 230000000968 intestinal Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 238000011084 recovery Methods 0.000 claims 2
- 230000003442 weekly Effects 0.000 claims 2
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 1
- WUBBRNOQWQTFEX-UHFFFAOYSA-N 4-Aminosalicylic acid Chemical compound NC1=CC=C(C(O)=O)C(O)=C1 WUBBRNOQWQTFEX-UHFFFAOYSA-N 0.000 claims 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 1
- 229940064701 Corticosteroid nasal preparations for topical use Drugs 0.000 claims 1
- 229960001334 Corticosteroids Drugs 0.000 claims 1
- 229940119017 Cyclosporine Drugs 0.000 claims 1
- 108010036949 Cyclosporine Proteins 0.000 claims 1
- 108091006004 Fc-tagged proteins Proteins 0.000 claims 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 1
- 229960003444 IMMUNOSUPPRESSANTS Drugs 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims 1
- 229960001967 Tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 1
- 230000003187 abdominal Effects 0.000 claims 1
- 230000000735 allogeneic Effects 0.000 claims 1
- 229940113720 aminosalicylate Drugs 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 230000003510 anti-fibrotic Effects 0.000 claims 1
- 229960000070 antineoplastic Monoclonal antibodies Drugs 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000003115 biocidal Effects 0.000 claims 1
- 102000008395 cell adhesion mediator activity proteins Human genes 0.000 claims 1
- 108040002558 cell adhesion mediator activity proteins Proteins 0.000 claims 1
- 229960001265 ciclosporin Drugs 0.000 claims 1
- 238000002648 combination therapy Methods 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 230000013872 defecation Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 1
- 239000002955 immunomodulating agent Substances 0.000 claims 1
- 230000002584 immunomodulator Effects 0.000 claims 1
- 229940121354 immunomodulators Drugs 0.000 claims 1
- 230000001861 immunosuppresant Effects 0.000 claims 1
- 230000001506 immunosuppresive Effects 0.000 claims 1
- 230000002757 inflammatory Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 229940079866 intestinal antibiotics Drugs 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229960000060 monoclonal antibodies Drugs 0.000 claims 1
- 102000005614 monoclonal antibodies Human genes 0.000 claims 1
- 108010045030 monoclonal antibodies Proteins 0.000 claims 1
- 230000004899 motility Effects 0.000 claims 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 1
- 238000001126 phototherapy Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 238000009097 single-agent therapy Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000002459 sustained Effects 0.000 claims 1
- 229940083878 topical for treatment of hemorrhoids and anal fissures Corticosteroids Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862633534P | 2018-02-21 | 2018-02-21 | |
| US62/633,534 | 2018-02-21 | ||
| PCT/US2019/019042 WO2019165140A1 (en) | 2018-02-21 | 2019-02-21 | DOSING FOR TREATMENT WITH IL-22 Fc FUSION PROTEINS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514354A JP2021514354A (ja) | 2021-06-10 |
| JPWO2019165140A5 true JPWO2019165140A5 (es) | 2022-03-02 |
Family
ID=65724526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020543145A Pending JP2021514354A (ja) | 2018-02-21 | 2019-02-21 | ＩＬ−２２Ｆｃ融合タンパク質による治療のための投与 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210139552A1 (es) |
| EP (1) | EP3755364A1 (es) |
| JP (1) | JP2021514354A (es) |
| KR (1) | KR20200123118A (es) |
| CN (1) | CN111757751A (es) |
| AU (1) | AU2019226085A1 (es) |
| CA (1) | CA3091139A1 (es) |
| IL (1) | IL276616A (es) |
| MA (1) | MA51907A (es) |
| MX (1) | MX2020008502A (es) |
| RU (1) | RU2020128111A (es) |
| SG (1) | SG11202007694UA (es) |
| TW (1) | TW201946647A (es) |
| WO (1) | WO2019165140A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术（上海）有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
| EP3442562B1 (en) | 2016-04-15 | 2022-09-21 | Evive Biotechnology (Shanghai) Ltd | An il-22 dimer for use in treating necrotizing enterocolitis |
| US20210023176A1 (en) * | 2019-07-26 | 2021-01-28 | Genentech, Inc. | DOSING FOR PREVENTION OR TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) WITH IL-22 Fc FUSION PROTEINS |
| JP2023513227A (ja) * | 2020-02-14 | 2023-03-30 | エバイブ バイオテクノロジー （シャンハイ） リミテッド | Ｉｌ－２２二量体を用いたウイルス誘発性臓器損傷又は不全の予防又は治療方法 |
| WO2021164744A1 (en) * | 2020-02-19 | 2021-08-26 | Evive Biotechnology (Shanghai) Ltd | Methods for treating graft versus host disease |
| WO2021207662A1 (en) * | 2020-04-10 | 2021-10-14 | Genentech, Inc. | Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4717717A (en) | 1986-11-05 | 1988-01-05 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| US5457093A (en) | 1987-09-18 | 1995-10-10 | Ethicon, Inc. | Gel formulations containing growth factors |
| US5705485A (en) | 1987-09-18 | 1998-01-06 | Ethicon, Inc. | Gel formulations containing growth factors |
| NZ226171A (en) | 1987-09-18 | 1990-06-26 | Ethicon Inc | Gel formulation containing polypeptide growth factor |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| EP0397687B1 (en) | 1987-12-21 | 1994-05-11 | The University Of Toledo | Agrobacterium mediated transformation of germinating plant seeds |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| US5130298A (en) | 1989-05-16 | 1992-07-14 | Ethicon, Inc. | Stabilized compositions containing epidermal growth factor |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US7018809B1 (en) | 1991-09-19 | 2006-03-28 | Genentech, Inc. | Expression of functional antibody fragments |
| WO1994029351A2 (en) | 1993-06-16 | 1994-12-22 | Celltech Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| GB9603256D0 (en) | 1996-02-16 | 1996-04-17 | Wellcome Found | Antibodies |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| CA2293829C (en) | 1997-06-24 | 2011-06-14 | Genentech, Inc. | Methods and compositions for galactosylated glycoproteins |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| EP1028751B1 (en) | 1997-10-31 | 2008-12-31 | Genentech, Inc. | Methods and compositions comprising glycoprotein glycoforms |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| JP2002510481A (ja) | 1998-04-02 | 2002-04-09 | ジェネンテック・インコーポレーテッド | 抗体変異体及びその断片 |
| ES2340112T3 (es) | 1998-04-20 | 2010-05-28 | Glycart Biotechnology Ag | Ingenieria de glicosilacion de anticuerpos para la mejora de la citotoxicidad celular dependiente de anticuerpos. |
| IL141688A0 (en) | 1998-09-04 | 2002-03-10 | Scios Inc | Hydrogel compositions for the controlled release administration of growth factors |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| PL209786B1 (pl) | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Hakko Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| DE60022369T2 (de) | 1999-10-04 | 2006-05-18 | Medicago Inc., Sainte Foy | Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| JP4668498B2 (ja) | 1999-10-19 | 2011-04-13 | 協和発酵キリン株式会社 | ポリペプチドの製造方法 |
| EP1331266B1 (en) | 2000-10-06 | 2017-01-04 | Kyowa Hakko Kirin Co., Ltd. | Cells producing antibody compositions |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US7064191B2 (en) | 2000-10-06 | 2006-06-20 | Kyowa Hakko Kogyo Co., Ltd. | Process for purifying antibody |
| NZ592087A (en) | 2001-08-03 | 2012-11-30 | Roche Glycart Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| MXPA04003798A (es) | 2001-10-25 | 2004-07-30 | Genentech Inc | Composiciones de glicoproteina. |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| US20040259150A1 (en) | 2002-04-09 | 2004-12-23 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to Fcgamma receptor IIIa |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| AU2003236015A1 (en) | 2002-04-09 | 2003-10-20 | Kyowa Hakko Kirin Co., Ltd. | Process for producing antibody composition |
| JP4832719B2 (ja) | 2002-04-09 | 2011-12-07 | 協和発酵キリン株式会社 | ＦｃγＲＩＩＩａ多型患者に適応する抗体組成物含有医薬 |
| JPWO2003084569A1 (ja) | 2002-04-09 | 2005-08-11 | 協和醗酵工業株式会社 | 抗体組成物含有医薬 |
| CN102911987B (zh) | 2002-04-09 | 2015-09-30 | 协和发酵麒麟株式会社 | 基因组被修饰的细胞 |
| US7361740B2 (en) | 2002-10-15 | 2008-04-22 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| BRPI0316779B1 (pt) | 2002-12-16 | 2020-04-28 | Genentech Inc | anticorpo humanizado que liga cd20 humano, composição, artigo manufaturado, método de indução da apoptose, método de tratamento de câncer cd20 positivo, métodos de tratamento de doenças autoimunes, ácidos nucléicos isolados, vetores de expressão, células hospedeiras, método para a produção de um anticorpo 2h7 humanizado, polipeptídeo isolado, formulação líquida, método de tratamento de artrite reumatóide (ra) e anticorpos de ligação de cd20 humanizados |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US20080241884A1 (en) | 2003-10-08 | 2008-10-02 | Kenya Shitara | Fused Protein Composition |
| CA2542125A1 (en) | 2003-10-09 | 2005-04-21 | Kyowa Hakko Kogyo Co., Ltd. | Process for producing antibody composition by using rna inhibiting the function of .alpha.1,6-fucosyltransferase |
| SI2380911T1 (en) | 2003-11-05 | 2018-07-31 | Roche Glycart Ag | ANTIGEN-RELATED PATIENTS WITH INCREASED ATTENTION ON THE RECEPTOR FC AND EFFECTORAL FUNCTION |
| WO2005053742A1 (ja) | 2003-12-04 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | 抗体組成物を含有する医薬 |
| RU2368622C2 (ru) | 2004-04-13 | 2009-09-27 | Ф.Хоффманн-Ля Рош Аг | Антитела к р-селектину |
| TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
| AU2005286607B2 (en) | 2004-09-23 | 2011-01-27 | Genentech, Inc. | Cysteine engineered antibodies and conjugates |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2006138468A2 (en) | 2005-06-17 | 2006-12-28 | Genentech, Inc. | Use of vegf for wound healing |
| US20080226635A1 (en) | 2006-12-22 | 2008-09-18 | Hans Koll | Antibodies against insulin-like growth factor I receptor and uses thereof |
| EP2560683B2 (en) | 2010-04-23 | 2022-07-20 | F. Hoffmann-La Roche AG | Production of heteromultimeric proteins |
| ES2676023T3 (es) * | 2013-03-15 | 2018-07-16 | F. Hoffmann-La Roche Ag | Polipéptidos de IL-22 y proteínas de fusión de IL-22 Fc y métodos de uso |
| CR20150477A (es) * | 2013-03-15 | 2015-10-26 | Genentech Inc | Polipéptidos de il-22 y proteínas de fusión de il-22 fc y métodos de uso |
| US20160287670A1 (en) * | 2013-11-07 | 2016-10-06 | Memorial Sloan-Kettering Cancer Center | Methods of use for il-22 in the treatment of gastrointestinal graft vs. host disease |
| CN106146668A (zh) * | 2015-04-01 | 2016-11-23 | 中国人民解放军第二军医大学 | 长效白细胞介素22的制备方法及其用途 |
| KR20180030180A (ko) * | 2015-07-16 | 2018-03-21 | 필로겐 에스.피.에이. | Il22 면역컨쥬게이트 |
-
2019
- 2019-02-21 AU AU2019226085A patent/AU2019226085A1/en not_active Abandoned
- 2019-02-21 RU RU2020128111A patent/RU2020128111A/ru unknown
- 2019-02-21 JP JP2020543145A patent/JP2021514354A/ja active Pending
- 2019-02-21 EP EP19710206.4A patent/EP3755364A1/en not_active Withdrawn
- 2019-02-21 MA MA051907A patent/MA51907A/fr unknown
- 2019-02-21 CN CN201980014830.0A patent/CN111757751A/zh active Pending
- 2019-02-21 SG SG11202007694UA patent/SG11202007694UA/en unknown
- 2019-02-21 MX MX2020008502A patent/MX2020008502A/es unknown
- 2019-02-21 KR KR1020207023400A patent/KR20200123118A/ko not_active Application Discontinuation
- 2019-02-21 WO PCT/US2019/019042 patent/WO2019165140A1/en active Application Filing
- 2019-02-21 TW TW108105889A patent/TW201946647A/zh unknown
- 2019-02-21 CA CA3091139A patent/CA3091139A1/en active Pending
-
2020
- 2020-08-10 IL IL276616A patent/IL276616A/en unknown
- 2020-08-20 US US16/998,597 patent/US20210139552A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2378446T3 (es) | Anticuerpos anti-TNF y metotrexato en el tratamiento concomitante de enfermedades autoinmunes | |
| US20210130451A1 (en) | Treatment for rheumatoid arthritis | |
| RU2020128111A (ru) | ВЕДЕНИЕ БЕЛКОВ СЛИЯНИЯ IL-22 Fc ДЛЯ ЛЕЧЕНИЯ | |
| AU2020203867A1 (en) | Cenicriviroc for the treatment of fibrosis | |
| JP2017512193A (ja) | Ｉｌ−４ｒアンタゴニストを投与することによる皮膚感染を処置するための方法 | |
| Gabay et al. | Biological agents in monotherapy for the treatment of rheumatoid arthritis | |
| JP2023138982A (ja) | インターロイキン－１７（ｉｌ－１７）アンタゴニストを使用して腱障害を治療する方法 | |
| US20190322734A1 (en) | Treatment paradigm | |
| JPWO2019165140A5 (es) | ||
| US20230416402A1 (en) | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2 | |
| US20230034186A1 (en) | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen | |
| TW202323296A (zh) | 組合療法 | |
| JP2017193541A (ja) | 関節リウマチを治療するための医薬組成物 | |
| US20240247071A2 (en) | Compositions and Methods for Enhancing Body Weight and Lean Muscle Mass Using Antagonists Against Leptin Receptor, GDF8 and Activin A | |
| CN108992671B (zh) | 一种药物组合物及其制备治疗肝损伤的药物中的用途 | |
| US11084879B2 (en) | Compositions and methods for treating pancreatitis and pain with death receptor agonists | |
| RU2818832C2 (ru) | Композиции и способы для повышения веса тела и сухой мышечной массы с применением антагонистов рецептора лептина, gdf8 и активина а | |
| JP2018070473A (ja) | 関節リウマチを治療するための医薬組成物 | |
| JP2023518815A (ja) | Ｉｌ６アンタゴニストによるｃｏｖｉｄ－１９肺炎を含む肺炎の治療方法 | |
| JP2023518812A (ja) | Ｃｏｖｉｄ１９肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ | |
| TW202206457A (zh) | 用於治療呼吸疾病之泛elr+ cxc趨化因子抗體 | |
| WO1998011917A1 (en) | Hiv-1 therapy with il-2 and anti-tnf antibody | |
| JPH03127740A (ja) | 悪性腫瘍治療剤 |